AI summary
The failed attempt to use AI for drug development highlights the significant gap between current AI capabilities and the complex reality of biological research.
AI-generated summary. Check the original reporting for context and accuracy.
The failed attempt to use AI for drug development highlights the significant gap between current AI capabilities and the complex reality of biological research.
AI-generated summary. Check the original reporting for context and accuracy.
This is the available feed excerpt, which may be shortened or in the publisher’s original language.
An investment research firm wanted to prove AI could revolutionize drug development. So they teamed up with Anthropic to see whether an unreleased version of Claude could make scorpion antivenom. It couldn't. It came up with some promising starting points, but nothing close to an actual drug, experts tell The Verge. Citrini Research, the firm behind the experiment, admitted that "none of us could claim to know anything about AI as it related to biology." That didn't stop it from trying to make a drug from scratch - or publishing a blog post titled "We Wanted to Use Claude to Create a New Drug. Here's What Happened." The account came comple … Read the full story at The Verge.
An automated sorting aid based on source trust, keywords, and entities, on a scale of 1–12. High: 9–12; medium: 6–8; low: 1–5. It does not measure urgency, verify reporting, or indicate editorial endorsement.
Smart bird feeders are heavily discounted, offering affordable, high-tech ways to watch birds from home without leaving the couch.
Coolpad’s $150 phone offers a wider, tablet-like screen at a fraction of the cost of premium folding devices, making this design trend accessible to budget buyers.